| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marona-Lewicka, Nichol. The Effect of Selective Serotonin Releasing Agents in the Chronic Mild Stress Model of Depression in Rats. Stress (Amsterdam, Netherlands). vol 2. issue 2. 2019-11-20. PMID:9787258. |
in single-bottle tests, chronic treatment with the selective 5-ht releasers, mmai (5 mg/kg, 2 x day) or mta (p-methylthioamphetamine; 5 mg/kg, 2 x day), reversed the deficit in rewarded behavior (anhedonia) measured as a decrease in the consumption of 1% sucrose solution in the chronic mild stress model of depression in rats. |
2019-11-20 |
2023-08-12 |
rat |
| A. Tazi, M. Farh, M. Moumni, F. Hakko. Potentiation of behavioural effects of a calcium channel antagonist, nifedipine, by ipsapirone. Behavioural pharmacology. vol 3. issue 3. 2019-11-20. PMID:11224126. |
the synergistic effect between the 5-ht(1a) agonist ipsapirone and the calcium channel antagonist, nifedipine, was studied in animal models of anxiety and depression. |
2019-11-20 |
2023-08-12 |
Not clear |
| Kumatoshi Ishihara, Taku Amano, Hiroshi Hayakawa, Shigeto Yamawaki, Masashi Sas. Enhancement of serotonin(1A) receptor function following repeated electroconvulsive shock in young rat hippocampal neurons in vitro. The international journal of neuropsychopharmacology. vol 2. issue 2. 2019-11-20. PMID:11281976. |
this supports the hypothesis that enhanced 5-ht(1a) receptor function, at least in part, contributes to the effectiveness of ecs treatment for depression directly and/or indirectly. |
2019-11-20 |
2023-08-12 |
rat |
| Klaus-Peter Lesch, Rainald Mössne. Knockout Corner: 5-HT(1A) receptor inactivation: anxiety or depression as a murine experience. The international journal of neuropsychopharmacology. vol 2. issue 4. 2019-11-20. PMID:11285149. |
knockout corner: 5-ht(1a) receptor inactivation: anxiety or depression as a murine experience. |
2019-11-20 |
2023-08-12 |
mouse |
| Klaus-Peter Lesch, Rainald Mössne. Knockout Corner: 5-HT(1A) receptor inactivation: anxiety or depression as a murine experience. The international journal of neuropsychopharmacology. vol 2. issue 4. 2019-11-20. PMID:11285149. |
5-ht(1a) receptors play a critical role in the pathophysiology of anxiety and depression as well as in the mode of action of anxiolytic and antidepressant drugs. |
2019-11-20 |
2023-08-12 |
mouse |
| Dirk van West, Michael Mae. Activation of the inflammatory response system: A new look at the etiopathogenesis of major depression. Neuro endocrinology letters. vol 20. issue 1-2. 2019-11-20. PMID:11473226. |
the reciprocal relationships between irs activation and hypothalamic-pituitary-adrenal (hpa)-axis hyperactivity, alterations in hp thyroid (hpt)-axis function and the availability of tryptophan to the brain led us to hypothesize that these neuroendocrine changes in depression are indicators of irs activation and that a combined dysregulation of the irs, the turnover of serotonin (5-ht) and the hpa-axis is an integral component of depression. |
2019-11-20 |
2023-08-12 |
Not clear |
| H. Bras, E. Jankowska, B. Noga, B. Skoo. Comparison of Effects of Various Types of NA and 5-HT Agonists on Transmission from Group II Muscle Afferents in the Cat. The European journal of neuroscience. vol 2. issue 12. 2019-11-20. PMID:12106064. |
the results suggest that this depression may involve different membrane receptors at different locations, primarily alpha2 adrenoceptors in the intermediate zone/ventral horn and 5-ht1a serotonin receptors in the dorsal horn. |
2019-11-20 |
2023-08-12 |
cat |
| Andreas Conca, Edgar Swoboda, Peter König, Stefan Koppi, Wolfgang Beraus, Arno Künz, Heinz Fritzsche, Peter Weis. Clinical impacts of single transcranial magnetic stimulation (sTMS) as an add-on therapy in severely depressed patients under SSRI treatment. Human psychopharmacology. vol 15. issue 6. 2019-11-20. PMID:12404305. |
in our 4 week study of stms, 12 patients affected by severe non-psychotic major depression (dsm-iii-r) were enrolled and put on standardized combined antidepressant medication with the serotonin re-uptake inhibitor citalopram, and the serotonin modulating drug, trazodone. |
2019-11-20 |
2023-08-12 |
Not clear |
| Johan A. Den Boer, Fokko J. Bosker, Bernhard R. Slaa. Serotonergic drugs in the treatment of depressive and anxiety disorders. Human psychopharmacology. vol 15. issue 5. 2019-11-20. PMID:12404310. |
5-ht(1a) agonists have been used extensively for the treatment of depression and gad but evidence of their efficacy in other anxiety disorders is equivocal. |
2019-11-20 |
2023-08-12 |
Not clear |
| John F. Cryan, Brian E. Leonar. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Human psychopharmacology. vol 15. issue 2. 2019-11-20. PMID:12404340. |
5-ht1a and beyond: the role of serotonin and its receptors in depression and the antidepressant response. |
2019-11-20 |
2023-08-12 |
human |
| John F. Cryan, Brian E. Leonar. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Human psychopharmacology. vol 15. issue 2. 2019-11-20. PMID:12404340. |
since its discovery 50 years ago, the role of the indoleamine 5-ht (5-hydroxytryptamine; serotonin) in the pathogenesis of depression and in the mechanism of action of antidepressant drugs has been the subject of considerable research. |
2019-11-20 |
2023-08-12 |
human |
| John F. Cryan, Brian E. Leonar. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Human psychopharmacology. vol 15. issue 2. 2019-11-20. PMID:12404340. |
this classification has led to the development of selective compounds that have aided in the efforts of dissecting the complex role of 5-ht in depression and in mediating the antidepressant response. |
2019-11-20 |
2023-08-12 |
human |
| John F. Cryan, Brian E. Leonar. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Human psychopharmacology. vol 15. issue 2. 2019-11-20. PMID:12404340. |
in addition, a number of postsynaptic 5-ht receptors have been shown to be dysfunctional in depression and are also potential targets for a number of antidepressants. |
2019-11-20 |
2023-08-12 |
human |
| I. Hindmarc. Expanding the horizons of depression: beyond the monoamine hypothesis. Human psychopharmacology. vol 16. issue 3. 2019-11-20. PMID:12404573. |
the monoamine hypothesis has dominated our understanding of depression and of pharmacological approaches to its management and it has produced several generations of antidepressant agents, ranging from the monoamine oxidase inhibitors (maois), through tricyclics (tcas) and selective serotonin reuptake inhibitors (ssris), to the recently introduced selective noradrenaline reuptake inhibitor (nari), reboxetine. |
2019-11-20 |
2023-08-12 |
human |
| A. B. Biswas, S. Bhaumik, D. Branfor. Treatment-emergent behavioural side effects with selective serotonin re-uptake inhibitors in adults with learning disabilities. Human psychopharmacology. vol 16. issue 2. 2019-11-20. PMID:12404583. |
selective serotonin re-uptake inhibitors are widely used for the treatment of depression suffered by adults with learning disabilities. |
2019-11-20 |
2023-08-12 |
Not clear |
| Boris Nemets, Mendel Fux, Joseph Levine, R. H Belmake. Combination of antidepressant drugs: the case of inositol. Human psychopharmacology. vol 16. issue 1. 2019-11-20. PMID:12404596. |
inositol is a second messenger precursor that is effective in depression and obsessive-compulsive disorder via a mechanism different from serotonin reuptake inhibitors. |
2019-11-20 |
2023-08-12 |
Not clear |
| Boris Nemets, Mendel Fux, Joseph Levine, R. H Belmake. Combination of antidepressant drugs: the case of inositol. Human psychopharmacology. vol 16. issue 1. 2019-11-20. PMID:12404596. |
however, controlled trials of inositol combined with serotonin reuptake inhibitors in depression or in reuptake inhibitor resistant depressed patients, or in partially responsive obsessive-compulsive patients, did not reveal added benefit. |
2019-11-20 |
2023-08-12 |
Not clear |
| P. Polla. [Psychic disorders] Revue neurologique. vol 158. issue 122. 2019-11-20. PMID:12690323. |
it is suggested that the first-line treatment of depression in parkinson's disease is the class of the selective serotonin reuptake inhibitors. |
2019-11-20 |
2023-08-12 |
Not clear |
| Iu P Sivola. [Treatment of alcohol dependence: rational and arguable approaches]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 114. issue 5 Pt 2. 2019-11-20. PMID:24988976. |
use of selective serotonin reuptake inhibitors including fluvoxamine for alcohol patients is of great importance due to frequent comorbidity of alcoholism, depression and anxiety. |
2019-11-20 |
2023-08-13 |
Not clear |
| Elyse C Dankoski, Susan Carroll, Robert Mark Wightma. Acute selective serotonin reuptake inhibitors regulate the dorsal raphe nucleus causing amplification of terminal serotonin release. Journal of neurochemistry. vol 136. issue 6. 2019-11-20. PMID:26749030. |
selective serotonin reuptake inhibitors (ssris) were designed to treat depression by increasing serotonin levels throughout the brain via inhibition of clearance from the extracellular space. |
2019-11-20 |
2023-08-13 |
mouse |